Avdoralimab: meta-analysis of COVID-19 studies

All studies Mortality Serious outcomes RCTs RCT mortality Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−68%

Mortality (1)−68%

RCTs (1)−68%

Late (1)−68%

00.511.5+

← Avdoralimab
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Avdoralimab COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Carvelli (DB RCT)−68%1.68 · 0.87–3.26death20/10312/104FORCE

Late treatment−68%1.68 · 0.87–3.2620/10312/10468% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.12

All studies−68%1.68 · 0.87–3.2620/10312/10468% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1200.511.52+

Rotate screen for more detailsIncrease width for more details

← Avdoralimab
reduces riskAvdoralimab
increases risk →

c19early.org

October 2026

Avdoralimab COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Carvelli (DB RCT)−68%1.68 · 0.87–3.2620/10312/104FORCE

Late treatment−68%1.68 · 0.87–3.2620/10312/10468% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.12

All studies−68%1.68 · 0.87–3.2620/10312/10468% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1200.511.52+

Rotate screen for more detailsIncrease width for more details

← Avdoralimab
reduces riskAvdoralimab
increases risk →

c19early.org

October 2026

Avdoralimab COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Carvelli (DB RCT)−68%1.68 · 0.87–3.26death20/10312/104FORCE

Late treatment−68%1.68 · 0.87–3.2620/10312/10468% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.12

All studies−68%1.68 · 0.87–3.2620/10312/10468% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1200.511.52+

Rotate screen for more detailsIncrease width for more details

← Avdoralimab
reduces riskAvdoralimab
increases risk →

c19early.org

October 2026

Avdoralimab COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Carvelli (DB RCT)−68%1.68 · 0.87–3.26death20/10312/104FORCE

Late treatment−68%1.68 · 0.87–3.2620/10312/10468% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.12

All studies−68%1.68 · 0.87–3.2620/10312/10468% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1200.511.52+

Rotate screen for more detailsIncrease width for more details

← Avdoralimab
reduces riskAvdoralimab
increases risk →

c19early.org

October 2026

Avdoralimab COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Carvelli (DB RCT)−68%1.68 · 0.87–3.2620/10312/104FORCE

Late treatment−68%1.68 · 0.87–3.2620/10312/10468% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.12

All studies−68%1.68 · 0.87–3.2620/10312/10468% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1200.511.52+

Rotate screen for more detailsIncrease width for more details

← Avdoralimab
reduces riskAvdoralimab
increases risk →

c19early.org

October 2026

Avdoralimab COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Carvelli (DB RCT)−68%1.68 · 0.87–3.26death20/10312/104FORCE

Late treatment−68%1.68 · 0.87–3.2620/10312/10468% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.12

All studies−68%1.68 · 0.87–3.2620/10312/10468% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1200.511.52+

Rotate screen for more detailsIncrease width for more details

← Avdoralimab
reduces riskAvdoralimab
increases risk →

c19early.org

October 2026

Avdoralimab COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Carvelli (DB RCT)−68%1.68 · 0.87–3.26death20/10312/104FORCE Carvelli (DB RCT)−96%1.96 · 0.52–7.40death6/503/49FORCE Carvelli (DB RCT)−108%2.08 · 0.42–10.34death4/242/25FORCE Carvelli (DB RCT)−48%1.48 · 0.65–3.36death10/297/30FORCE

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Avdoralimab
reduces riskAvdoralimab
increases risk →